Dr. Salgia on FDA Approval of Lorlatinib in ALK+ NSCLC
November 3rd 2018Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the FDA approval of lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer.
Read More
Dr. Salgia on Crizotinib and Other TKIs in ALK-Positive NSCLC
February 19th 2018Ravi Salgia, MD, PhD, associate director, Clinical Sciences Research, Arthur & Rosalie Kaplan Chair, Medical Oncology, professor and chair, Department of Medical Oncology & Therapeutics Research, City of Hope, discusses effective agents in the treatment of patients with ALK-positive tumors.
Read More